for the patient diagnosed with gastic GIST , they underwent subtotal or total gastrectomy.

Gastric GIST

total or subtotal gastrectomy

Prognostic Factors Affecting Survival of Gastric GIST

Clinicopathological Characteristics and Prognostic Factors of Gastrointestinal Stromal Tumors Located in the Stomach in Tunisian Patients

the patient having adenocarcinoma or other histopathological type are excluded

ammar houssem

Doctor

Université de Sousse

Anrotenil hydrochloride capsule was used to treat soft tissue sarcomas with first-line chemotherapy failure (doxorubicin + ifosfamide). Oral administration was conducted on an empty stomach before breakfast (12mg), and the drug was discontinued for 2 weeks for one week (3 weeks for one cycle) until the disease progressed or became intolerable.

Soft Tissue Sarcomas

The standard first-line chemotherapy regimen (adriamycin + ifosfamide) failed

Anlotinib Hydrochloride

Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital

Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule

There are and only 50% of individuals who survive this time

The percentage of patients whose tumors have shrunk to a certain amount of time and stayed that way for a certain amount of time

In order to better conduct clinical studies and ensure the prospective and timeliness of the studies, patients' IPD will be kept confidential.

YaoWeitao

Chief physician

Henan Cancer Hospital

Olaparib (given orally at a dose of 300 mg twice a day) in combination with Durvalumab (given intravenously at a dose of 1500 mg every 4 weeks)

Cediranib (given orally at a dose of 20 mg daily, 5 days on 2 days off) in combination with Durvalumab (given intravenously at a dose of 1500 mg every 4 weeks)

Mismatch Repair Proficient Colorectal Cancer

Pancreatic Adenocarcinoma

Leiomyosarcoma

Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.

Durvalumab

Olaparib (AZD2281) is a potent oral poly Poly (ADP-ribose) Polymerase (PARP) enzyme inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents. Olaparib specifically traps PARP1 and PARP2 enzymes at sites of damaged DNA; the trapped PARP1- or PARP2-DNA complex is cytotoxic and produces clinical response. Although olaparib also binds to PARP3, recent investigations have suggested PARP-3 inhibition does not contribute towards anti-cancer activity.

Olaparib

Cediranib (AZD2171) is a potent oral small molecule Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinase inhibitor, specifically inhibiting all three VEGF receptors (VEGFR-1, -2 and -3). It has additional inhibitory activity against stem cell factor receptor tyrosine kinase, and less potency against platelet-derived growth factor receptor tyrosine kinases. Cediranib exerts its anti-angiogenic property by competitively inhibiting the ATP binding site on the VEGF receptors.

Cediranib

Princess Margaret Cancer Centre

Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

If a departure from the normal distribution will be noticed for the distributions of the CD8 and CD4 then a log-transformation will be applied. The CD8 and CD4 will be compared between responders and non-responders by applying the t-test. Subgroup analysis based on the site will also be attempted.

University Health Network, Toronto

AstraZeneca

The combination of lenvatinib and eribulin

Liposarcoma

Soft Tissue Sarcoma Adult

Advanced Cancer

lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days

Eribulin

Lenvatinib

National Taiwan University Hospital

Taipei Veterans General Hospital

Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma

A Single-arm Phase Ib/II Study of the Combination of Lenvatinib and Eribulin in Advanced Adipocytic Sarcoma and Leiomyosarcoma (LEADER Study)

We will measure the radiographic changes of the tumor based on a prespecified criteria called RECIST (Response evaluation criteria in solid tumors). A tumor decreased in the sum of longest diameters of measurable tumors of more than 30% is considered responsive; a growth of tumor more than 20% in the sum of the longest diameter is considered disease progression; and shrinkage or growth between these intervals is considered stable disease (SD).

We will measure how many patients (proportion) of the participants that the tumor has progressed in the first 24 weeks of treatment

The definition of 12-months OS rate is the percentage of patients who had NOT has an event before or at 12 months. An event is defined as follows: Death due to any cause.

The definition of 6 months OS rate is the percentage of patients who had NOT has an event before or at 6 months. An event is defined as follows: Death due to any cause.

Toxicities will be assessed according to CTCAE 4.03. The number of all grade toxicities will be recorded

leiomyosarcoma/tyrosine

Prognostic Factors Affecting Survival of Gastric GIST

Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule

Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen